Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J

Canadian journal of diabetes3 May 2014Cited by 33 (Europe PMC)

PMID24797495DOI10.1016/j.jcjd.2013.10.006PepBankPUB-24797495

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In type 1 diabetes, adjunctive weekly exenatide was linked to a 0.6% A1C reduction from baseline.
In plain wordsIn type 1 diabetes, added weekly exenatide was linked to lower A1C compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C
Study
n = 11
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 3 monthsAs given in this study (human).
Measurements
A1C reduction from baseline
0.6%
3 months after starting once-weekly exenatide
Source sentences
Summary
Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included.
Summary · context
An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria.
Report a problemFND-2479749501
02HumanObservational studyEfficacy outcome
In type 1 diabetes, adjunctive weekly exenatide was linked to a 3.7% body weight reduction from baseline.
In plain wordsIn type 1 diabetes, added weekly exenatide was linked to lower body weight compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 11
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 3 monthsAs given in this study (human).
Measurements
Body weight reduction from baseline
3.7%
3 months after starting once-weekly exenatide
Source sentences
Summary
Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included.
Summary · context
An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria.
Report a problemFND-2479749502
03HumanObservational studyEfficacy outcome
In type 1 diabetes, adjunctive weekly exenatide was linked to a 1.7 kg/m(2) body mass index reduction from baseline.
In plain wordsIn type 1 diabetes, added weekly exenatide was linked to lower body mass index compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody mass index
Study
n = 11
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 3 monthsAs given in this study (human).
Measurements
Body mass index reduction from baseline
1.7 kg/m(2)
3 months after starting once-weekly exenatide
Source sentences
Summary
Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included.
Summary · context
An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria.
Report a problemFND-2479749503
04HumanObservational studyEfficacy outcome
In type 1 diabetes, adjunctive weekly exenatide was linked to a 13% total daily insulin dose reduction from baseline.
In plain wordsIn type 1 diabetes, added weekly exenatide was linked to a lower total daily insulin dose compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal daily insulin dose
Study
n = 11
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 3 monthsAs given in this study (human).
Measurements
Total daily insulin dose reduction from baseline
13%
3 months after starting once-weekly exenatide
Source sentences
Summary
Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included.
Summary · context
An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria.
Report a problemFND-2479749504
05HumanObservational studyEfficacy outcome
In type 1 diabetes, adjunctive weekly exenatide was linked to a 9.3-unit bolus insulin dose reduction from baseline.
In plain wordsIn type 1 diabetes, added weekly exenatide was linked to a lower bolus insulin dose compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBolus insulin dose
Study
n = 11
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 3 monthsAs given in this study (human).
Measurements
Bolus insulin dose reduction from baseline
9.3 units
3 months after starting once-weekly exenatide
Source sentences
Summary
Comparing baseline and 3 months after initiation of once-weekly exenatide revealed reductions of 0.6% in A1C (p=0.013), 3.7% in body weight (p=0.008), 1.7 kg/m(2) in body mass index (p=0.003), 13% in total daily insulin dose (p=0.011) and 9.3 units in bolus insulin dose (p=0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
For this retrospective study, patients with type 1 diabetes, aged 18 years and older, receiving continuous subcutaneous insulin infusion, using a continuous glucose monitoring device or regularly measuring blood glucose levels and receiving 2 mg of exenatide once weekly for at least 3 months were included.
Summary · context
An electronic medical record search identified 11 patients with type 1 diabetes who met the inclusion criteria.
Report a problemFND-2479749505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords